Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo

Prostate

Volumn 65, Issue 1, 2005, Pages 10-19

  Hayashi, Norihiro ^a   Asano, Koji ^a   Suzuki, Hideaki ^a   Yamamoto, Tetsuhisa ^b   Tanigawa, Nobuhiko ^b   Egawa, Shin ^a   Manome, Yoshinobu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Adenovirus vector; Antisense; Chemotherapy; Prostate cancer; Survivin

Indexed keywords

ADENOVIRUS VECTOR; ANDROGEN; BETA GALACTOSIDASE; COMPLEMENTARY DNA; DOCETAXEL; ETOPOSIDE; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIZATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTISENSE ELEMENTS (GENETICS); APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; ETOPOSIDE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 24944527451     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20232     Document Type: Article

References (30)

1. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998;160(4):1220-1229.
2. Syed S. Combination chemotherapy for hormone-refractory prostate carcinoma: Progress and pitfalls. Cancer 2003;98:2088.
3. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in survivin-targeted melanoma cells. Oncogene 2004;23:39.
4. Blanc-Brude OP, Mesri M, Wall NR, et al. Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003;9:2683.
5. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43.
6. Karaburun Paker S, Kilicarslan B, Ciftcioglu AM, et al. Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer. Pathol Oncol Res 2001;7:209.
7. Zellweger T, Ninck C, Mirlacher M, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003;55:20.
8. Bauer JJ, Sesterhenn IA, Mostofi EK, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996;156:1511.
9. Lipponen P, Vesalainen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Prostate 1997;32:9.
10. Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003;9:4914.
11. Kaur P, Kallakury BS, Sheehan CE, et al. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004;128:39.
12. Shariat SF, Casella R, Khoddami SM, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171:626.
13. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580.
14. Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002;62:2462.
15. Yamamoto T, Manome Y, Nakamura M, et al. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 2002;38:2316.
16. Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998;273:11177.
17. Oudard S, Legrier ME, Boye K, et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003;169:1729.
18. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315.
19. Ito T, Shiraki K, Sugimoto K, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000;31:1080.
20. Grossman D, Kim PJ, Schechner JS, et al. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001;98:635.
21. Chen J, Wu W, Tahir SK, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000;2:235.
22. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000;60:2805.
23. Pennati M, Binda M, De Cesare M, et al. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004;25:1129-1136.
24. Pennati M, Binda M, Colella G, et al. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 2004;23:386.
25. Choi KS, Lee TH, Jung MH. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 2003;10:87.
26. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001;108:981.
27. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115:575.
28. Xing Z, Conway EM, Kang C, et al. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 2004;199:69.
29. Kamradt JM, Pienta KJ. Etoposide in prostate cancer. Expert Opin Pharmacother 2000;1:271.
30. Oh WK. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. J Urol 2003;170:328.